Drug Delivery Vehicle—Teriflunomide Interactions Affect Treatment and Fluorine Magnetic Resonance in an Animal Model of Multiple Sclerosis

Background/Objectives: Teriflunomide (TF) is a fluorinated oral therapy approved for relapsing-remitting multiple sclerosis that can be detected using fluorine-19 (19F) magnetic resonance (MR) methods. In preclinical studies, palatable drug delivery vehicles may facilitate voluntary oral administration and reduce procedure-related stress; however, they may also interact with the drug and alter its pharmacological and MR properties. We investigated whether sweetened milk (SM), compared with sucrose-containing carboxymethylcellulose (SCMC), affects the therapeutic efficacy, tissue distribution, and 19F MR signal of TF in experimental autoimmune encephalomyelitis (EAE), a mouse model of MS.